Affymetrix (www.affymetrix.com) granted Empire Genomics (www.empiregenomics.com) a number of patents related to comparative genomic hybridization (CGH). The nonexclusive, worldwide license includes IP covering the manufacturing, use, and sale of nucleic acid microarrays and related products and services for CGH. “We fully expect,” states Anthony Johnson, president and CEO of Empire Genomics, “that focusing in the field of copy number variation will lead to the discovery of the genomic causes of multiple diseases as well as advanced therapeutic treatment strategies.”
